This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 1999;282:1613.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

There is a continuing, serious shortage of immune globulin intravenous (IGIV), a plasma-derived product approved for the treatment of primary immunodeficiency, immune-mediated thrombocytopenia (ITP), Kawasaki disease, bone marrow transplantation, chronic B-cell lymphocytic leukemia, and human immunodeficiency virus type 1 (HIV-1) in pediatric patients.

The amount of IGIV distributed in the first 7 months of 1999 (8919 kg) was about 10% below the amount distributed in 1996 and nearly the same as in the first 7 months of 1998 (8746 kg). The consequences of this shortage were indicated in a March 1998 survey by the Immune Deficiency Foundation, which found that 86% of physicians treating immunodeficient patients with IGIV had difficulty obtaining the product (MMWR Morb Mortal Wkly Rep. 1999;48:159-162). A more recent survey by IDF has found only a slight improvement in this situation.

A possible contributing reason for the short supply is off-label use of IGIV. While there . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Structural Basis of Synercid(R) (Quinupristin-Dalfopristin) Resistance in Gram-positive Bacterial Pathogens
Kehoe et al.
J. Biol. Chem. 2003;278:29963-29970.
ABSTRACT | FULL TEXT